Papillary thyroid cancer (PTC) is a common malignancy and has a good prognosis after appropriate treatment. PTC cells spread mainly by lymph node metastasis (LNM), but the mechanism is not well understood. Expression of vascular endothelial growth factor C (VEGF-C) and matrix metalloproteinase 2 (MMP-2) protein was studied immunohistochemically from the archived specimens of 65 PTC patients who initially presented without LNM. In this retrospective study, the frequency of expression differed significantly between thyroid cancer tissue and adjacent normal follicular epithelium (VEGF-C 78.5% and 20.0%, respectively; MMP-2 81.5% and 36.7%, respectively). LNM developed in 35 of the patients during 5 -15 years of follow-up, by the end of which the frequencies of expression of VEGF-C and MMP-2 protein expression were 91.4% and 94.3%, respectively. Both VEGF-C and MMP-2 protein expression were significantly more frequent in PTC with LNM than without LNM. VEGF-C and MMP-2 protein expression levels were significantly correlated with LNM and it is, therefore, feasible that VEGF-C and MMP-2 may be useful as tumour markers of PTC with cervical LNM.
Introduction
Thyroid carcinoma is one of the most common malignancies and, compared with other malignancies, has some specific characteristics as regards biological behaviour, histology and therapeutic approaches. In America, the incidence of thyroid cancer has increased from 3.6 per 100 000 in 1973 to 8.7 per 100 000 in 2002. 1 Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid carcinoma (DTC), accounting for at least 70% of all follicular-cell derived thyroid malignancies. 2 It has been reported that primary lymph node metastases (LNM) are present in approximately 30 -40% of adult patients and that microscopic involvement of the lymph nodes occurs in as many as 80 -90% of patients. 3 Many authors have reported that LNM are associated with an increased rate of locoregional recurrence of disease but not with survival. 4 6, 7 Moreover, lymph node recurrences are distressing for patients. The clinical management of LNM, including the extent of initial surgery and the proper indication for radioiodine therapy, is still controversial. The optimal combined treatment for LNM requires a better understanding of the underlying molecular mechanism, and we still do not know how to predict cervical LNM in patients with PTC.
In this investigation, we determined whether the expression levels of vascular endothelial growth factor C (VEGF-C) and matrix metalloproteinase 2 (MMP-2) proteins differed between PTC patients with and without LNM. We tested the hypothesis that PTC that metastasizes to the lymph nodes expresses more VEGF-C and MMP-2 than PTC that does not metastasize.
Materials and methods

TISSUE SAMPLES
Human archival tissue samples were obtained from the pathology centre at the Provincial Hospital affiliated to Shandong University. The specimens were from 65 patients, comprising 11 who underwent radical neck dissection and 54 who underwent modified neck dissection between June 1989 and December 2004. None of the patients had LNM, as diagnosed by pathological examination. Thirty normal thyroid tissue specimens were collected from the postoperative tissue of benign thyroid disease for comparison.
IMMUNOHISTOCHEMISTRY
The streptavidin-peroxidase immunohistochemistry method was used to detect the protein expressions of VEGF-C and MMP-2. Rat anti-VEGF-C polyclonal antibody (1:100) and mouse anti-MMP-2 monoclonal antibody (1:40) were provided by Beijing Zhong Shan Biotechnology Co. Ltd, Beijing, China. Formalin-fixed, paraffin-embedded tissue sections 5 µm thick were used. A microwave oven was used for antigen retrieval. Specimens positive for VEGF-C and MMP-2 were used as positive controls.
Immunohistochemistry results were scored semi-quantitatively as follows (staining grade): 0, no staining; 1, pale yellow staining; 2, brown-yellow staining; and 3, chocolatebrown staining. Negative cells were those that scored 0 -1 and positive cells were those that scored 2 -3. Four grades of staining were set, according to the percentage of positive cells within a field of view (positive cells grade), as follows: grade 0, < 10% positive cells; grade 1, 11 -25%; grade 2, 26 -50%; grade 3, 51 -75%; and grade 4, > 75%. The calculation of 'staining grade' × 'positive cells grade' was then performed to provide a measure of overall immunohistochemical positivity, as follows: 0, negative (-), 1 -4, weakly positive (+), 5 -8, moderately positive (++), 9 -12, strongly positive (+++).
STATISTICAL ANALYSIS
The χ 2 test was used to test significant differences between pairs of groups. Pearson's contingency coefficient (C) was used to test for association analysis between VEGF-C and MMP-2 protein. A P-value of < 0.05 was considered significant.
Results
The 65 patients comprised 21 males and 44 females, with a mean age of 41 years (range 18 -56 years). During the follow-up period of 5 -15 years, 35 patients developed LNM and subsequently underwent radical neck dissection, and 30 had no LNM.
VEGF-C expression was found to occur in the cytoplasm. A significant difference in VEGF-C protein expression was found between PTC and normal thyroid tissue (51/65 [78.5%] Of the 65 patients included in this study, 43 (66.2%) showed coexpression of VEGF-C and MMP-2. Expression of VEGF-C protein was found to be significantly correlated with MMP-2 protein expression in PTC tissue (χ 2 = 4.875; P < 0.05, Pearson's coefficient of contingency, C = 0.517) ( Table 3 ).
Discussion
PTC is one of the most common forms of cancer, however it has a good prognosis following appropriate treatment. It mainly spreads through LNMs and is distressing for patients who suffer from frequent LMN recurrences. The mechanisms underlying LNM in PTC are not well understood.
A number of reports in the literature show increased expression of VEGF-C mRNA in 
TABLE 1:
Expression of vegetative endothelial growth factor C (VEGF-C) protein in thyroid papillary cancer tissue Lymph node metastasis in papillary thyroid cancer lymph node-invasive thyroid tumours. For example, patients with papillary carcinoma and nodal involvement have been shown to have significantly greater expression of VEGF-C mRNA than those without nodal involvement, 8 and the number of metastatic lymph nodes has been found to be positively correlated with VEGF-C mRNA expression in the primary tumour. 9 In the present study, the frequency of VEGF-C protein expression was significantly greater in PTC tissue than in normal thyroid tissue, and was also significantly greater in samples from PTC patients with LNM than in those without LNM. Thus, the expression of VEGF-C protein in PTC is related to the biological characteristics of PTC, i.e. the occurrence of LNMs. VEGF-C was first discovered and identified as a ligand of the tyrosine kinase receptor flt-4 (also known as VEGF receptor 3 [VEGFR-3]), which is expressed on lymphatic endothelium in adult skin and vascular tumours. By activating flt-4, VEGF-C induces proliferation of lymphatic endothelial cells in vitro 10 and lymphangiogenesis in vivo. 11 Animal experiments have shown that overexpression of VEGF-C in the skin of transgenic mice resulted in proliferation and enlargement of lymphatic endothelium, but not of vascular endothelium. 12 In two breast carcinoma models, VEGF-C was shown to induce tumour lymphangiogenesis and promote LNM. 13, 14 Observations from other non-thyroid experimental models and clinical studies have illustrated the critical role of MMP-2 in tumour progression. High levels of MMP-2 expression are associated with aggressive tumour behaviour and phenotype in many carcinomas. 15 Elevated levels of MMP-2 in PTC have been shown to correlate with the presence of LNM, 16, 17 although another study found no significant difference between MMP-2 protein expression in PTC with and without LNM. 18 MMPs are proteolytic enzymes that degrade components of the extracellular matrix and basement membrane and are involved in many aspects of tumour progression: tumour establishment, growth, angiogenesis, intravasation, extravasation, and almost all stages of metastasis. In thyroid neoplasia, MMPs, particularly MMP-2, seem to be associated with metastatic potential. 16, 19 In the present study there was a statistically significant difference in MMP-2 expression not only between PTC tissue and normal thyroid tissue, but also between samples from patients who developed LNM and those who did not develop LNM. This shows that the increased level of MMP-2 protein expression in the primary tumours and metastases of PTC is related to the frequency of cervical LNM in this disease. MMP-2 may, therefore, be involved in stimulating the lymphatic route of metastases in PTC.
The expression levels of VEGF-C and MMP-2 proteins in PTC are of considerable importance. The binding of VEGF-C and its receptor, VEGFR-3, may not only promote hyperplasia of blood vessels in tumours and tumour cell growth but also activate MMP-2. The regulation and mechanisms of action VEGF-C and MMP-2 in the formation of PTC and its invasive activity need further study. We found that the frequencies of expression Association analysis of expression of vegetative endothelial growth factor C (VEGF-C) and matrix metalloproteinase (MMP-2) protein in papillary thyroid cancer X Tian, M Cong, W Zhou et al. Lymph node metastasis in papillary thyroid cancer of VEGF-C and MMP-2 in patients who developed LNM in the follow-up period in our study, were markedly higher than in patients who did not develop LNM. It is possible, therefore, that it might be possible to use the raised expression levels of VEGF-C and MMP-2 to predict the future occurrence of cervical LNM in LNM-free PTC patients. These levels of expression may also have value in helping to decide whether to perform selective neck dissection in lymphatic-negative patients with PTC.
In conclusion, the expression levels of VEGF-C and MMP-2 were found to be closely related to the development of LNM in patients with PTC. It might be possible to use VEGF-C and MMP-2 as potential tumour markers of PTC with cervical LNM.
